This study will determine if daily oral intake of 200g of a marketed yogurt with fortified calcium content and a milk basic protein (MBP)80 mg benefits on bone cells activity in postmenopausal women. The efficacy of the product is measured by examining the variation of biochemical markers of bone turnover. MBP 80 is a particular protein contained in milk; it has been added to the yogurt provided for this study. The effects of MBP 80 on the quality of bone tissue have not yet been proven.

A 12-week, Open-label Study to Evaluate the Effect of MBP-80 (200g of Yogurt With Fortified Calcium Content and MBP 80 mg) on Bone Remodelling as Assessed by Bone Turnover Markers in Early Postmenopausal Women

The primary efficacy variable, the median percent change from baseline (Day 0) in levels of serum β-CTX (sCTX) at week 12, will be compared to the corresponding median percent change from day minus 28 (Day - 28) in levels of serum β-CTX (sCTX) at Day 0 for each participant.

A secondary efficacy variable, the median percent change from baseline (Day 0) in levels of serum P1NP (sP1NP) at week 12, will be compared to the corresponding median percent change from day minus 28 (Day - 28) in levels of serum P1NP(sP1NP) at Day 0 for each participant.

A secondary efficacy variable, the median percent change from baseline (Day 0) in levels of serum β-CTX(sCTX) at week 4, will be compared to the corresponding median percent change from day minus 28 (Day - 28) in levels of serum β-CTX(sCTX) at Day 0 for each participant.

A secondary efficacy variable, the median percent change from baseline (Day 0) in levels of urinary NTX(uNTX) at weeks 4 and 12, will be compared to the corresponding median percent change from day minus 28 (Day - 28) in levels of urinary NTX(uNTX) at Day 0 for each participant.

A secondary efficacy variable, the median percent change from baseline (Day 0) in levels of serum osteocalcin(sOC) at week 12, will be compared to the corresponding median percent change from day minus 28 (Day - 28) in levels of serum osteocalcin(sOC) at Day 0 for each participant.

Intake of one container of vanilla or strawberry yogurt in the morning on a daily basis during 12 weeks.

Other Name: Yoplait Asana TM

Detailed Description:

The morbidity and mortality associated with osteoporotic related fractures is devastating in terms of disability to an individual and cost to the global economy. As the world's population ages, this will present a major public health issue since a larger proportion of women remain undiagnosed and untreated even with the availability of therapies and calcium and vitamin D supplements. Consequently, it remains important to evaluate dairy products (milk, cheese, and yogurt) that can be safely provided as a supplement for bone health in addition to the current pharmacological treatments.

The rationale of this study is to assess the beneficial effect of a daily dietary supplement of MBP 80 mg in a yogurt matrix with fortified calcium content on bone remodelling in healthy early postmenopausal women with neither osteoporosis nor estrogens/progestin therapy.

Eligibility

Ages Eligible for Study:

45 Years to 60 Years

Genders Eligible for Study:

Female

Accepts Healthy Volunteers:

Yes

Criteria

Inclusion Criteria:

Early postmenopausal women, aged 45-60 yrs old inclusive, with 1-5 yrs since last menses; naturally or surgically menopausal as a result of bilateral oophorectomy. Hysterectomized (≤ 5 yrs) women 50-60 yrs old.

Any unapproved hormone-like treatment in the opinion of the Principal Investigator (P.I.), i.e. phytoestrogens, isoflavones, etc.

Antacids, H2 blockers, proton pump inhibitors for > 10 days

Iron supplements for > 10 days

Any condition or disease that may, according to the P.I., interfere with the evaluation of L.S. and Hip BMD; including but not limited to: advanced scoliosis or extensive lumbar fusion, less than 2 lumbar vertebrae (L1-L4) evaluable for DXA.

Hyper or hypothyroidism: patients on stable dose of thyroid treatment with normal TSH will be allowed. Lab values for TSH must be normal or slightly abnormal, though clinically non significant in the opinion of the P.I.

Variation of more than 2 kg (gain or loss) within 2 months of the Screening.

Presence of any vertebral fracture on the screening VFA (Vertebral Fracture Assessment) measured by DXA.

Any previous or ongoing clinically significant illness that, in the opinion of the P.I., could prevent the patient from completing the study.

Evidence of alcohol or substance abuse within the last 12 months that the P.I. believes would interfere with understanding or completing the study.

Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures.

Subject is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug trial(s), or subject is receiving other investigational agent(s).

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01501344